StockData
KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30

KAZIA THERAPEUTICS LTD

Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Nov 7, 2025
$7.85+0.60 (+8.28%)

Close on Oct 19, 2026

Kazia Therapeutics statistics

Financials through Dec 31, 2025, price-based ratios appear once a share price is available, median of Pharmaceutical Preparations companies for comparison

Valuation

MeasureKazia TherapeuticsIndustry median
Market CapA$18.21MA$18.21M
Enterprise Value-A$51.15MA$11.71M
PS Ratio433.54

Enterprise value

MeasureKazia TherapeuticsIndustry median
EV / Sales-1217.92

Income (trailing twelve months)

MeasureKazia TherapeuticsIndustry median
RevenueA$42.00K
Pretax Income-A$22.45M-A$22.45M
Net Income-A$20.70M
EPS (Diluted)-0.04 AUD

Margins

MeasureKazia TherapeuticsIndustry median
Pretax Margin-53447.6%
Profit Margin-49290.5%

Returns

MeasureKazia TherapeuticsIndustry median
Return on Assets (ROA)-46.5%

Growth

MeasureKazia TherapeuticsIndustry median
Revenue Growth (YoY)-98.2%

Balance sheet

MeasureKazia TherapeuticsIndustry median
Cash & Short-Term InvestmentsA$69.46MA$37.32M
Total DebtA$98.81K
Net Cash (Debt)A$69.36MA$37.32M
Net Cash Per Share0.09 AUD0.05 AUD
Working CapitalA$45.61MA$42.67M

Financial position

MeasureKazia TherapeuticsIndustry median
Current Ratio2.877.26
Quick Ratio2.865.84

Cash flow (trailing twelve months)

MeasureKazia TherapeuticsIndustry median
Operating Cash Flow-A$13.28M-A$13.28M

Efficiency

MeasureKazia TherapeuticsIndustry median
Asset Turnover0.00
Revenue Per EmployeeA$3.00K
Profits Per Employee-A$1.48M
Employee Count14

Dividends and yields

MeasureKazia TherapeuticsIndustry median
Earnings Yield-113.7%
Buyback Yield-64.6%
Shareholder Yield-64.6%

Shares

MeasureKazia TherapeuticsIndustry median
Shares Outstanding809,419,000322,848,000
Shares Change (YoY)107.8%28.6%
Float807,064,000316,596,000
Shares Held by Insiders0.29%1.94%
Shares Held by Institutions0.45%

Taxes

MeasureKazia TherapeuticsIndustry median
Income Tax-A$1.75M

Scores

MeasureKazia TherapeuticsIndustry median
Altman Z-Score-1.65-0.54
Piotroski F-Score2

Calculated by StockData from Kazia Therapeutics's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.